MSLN single-domain antibody and application thereof
By developing high-affinity MSLN single domain antibodies, the problem of difficult to achieve efficient and accurate deep penetration and rapid clearance of antibodies in the treatment of ovarian cancer in the prior art is solved, and a novel antibody with high binding and activeness is provided for ovarian cancer. The diagnosis and treatment of the disease have achieved a more effective treatment plan.
Patent Information
- Application Number
- CN202411268881.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-11
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-09-11
AI Technical Summary
Existing antibodies are difficult to achieve efficient and accurate diagnosis and treatment of ovarian cancer in tumor-targeted therapy, especially in terms of penetration and rapid clearance of deep tissues.
A high-affinity MSLN single domain antibody was developed, and its amino acid sequence was shown in SEQ ID No.1. The immunoalpapaus nanoantibody gene bank was designed, screened and expressed through phage display, and MSLN single with high binding force and activity was prepared. Domain antibodies, drugs and kits for the preparation of ovarian cancer.
It provides a MSLN single domain antibody with high activity, strong binding and high affinity, with an affinity constant of 2.52×10-8M, providing a new diagnostic and treatment plan for ovarian cancer, significantly improving the accuracy and effectiveness of the treatment. sex.
Smart Images

Figure CN119019559A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology, and in particular to a MSLN single domain antibody and an application thereof. Background Art
[0002] Mesothelin (MSLN) is a cell surface glycoprotein that is a splice variant of a precursor protein. It was first discovered in mesothelioma cells, hence the name. MSLN is upregulated in a variety of tumors, including pancreatic cancer, ovarian cancer, etc., while its expression in normal tissues is relatively low. This specific high expression in tumor tissues makes MSLN an attractive target for cancer therapy.
[0003] Single-domain antibodies (sdAbs) are a class of small antibody fragments of heavy-chain antibodies, which have the characteristics of small molecular weight, strong tissue penetration, high stability and low production cost. Compared with traditional monoclonal antibodies, single-domain antibodies have shown great potential in the targeted treatment of tumors, especially in achieving deep penetration and rapid clearance of tumor tissues.
[0004] Given the high expression of MSLN in a variety of tumors and the unique advantages of single-domain antibodies, the development of single-domain antibodies targeting MSLN has important clinical significance. This new antibody can specifically recognize and bind to MSLN, and is expected to play an important role in the diagnosis and treatment of ovarian cancer, providing patients with more effective and precise treatment options. Summary of the invention
[0005] In view of this, the present invention proposes a MSLN single-domain antibody with higher affinity and its application.
[0006] The technical solution of the present invention is implemented as follows: On the one hand, the present invention provides a MSLN monoclonal antibody, and the amino acid sequence of the MSLN single domain antibody is shown in SEQ ID No.1.
[0007] On the other hand, the present invention also provides a use of a MSLN single domain antibody in the preparation of a drug for treating ovarian cancer.
[0008] On the other hand, a pharmaceutical composition contains the MSLN single domain antibody shown in SEQ ID No.1.
[0009] On the other hand, a kit contains the MSLN single domain antibody shown in SEQ ID No.1.
[0010] The MSLN single domain antibody and its application of the present invention have the following beneficial effects compared with the prior art: the MSLN single domain antibody provided by the present invention has high activity, strong binding force with antigen, and high affinity, and the affinity constant reaches 2.52×10 -8 M, provides a new antibody and treatment option for ovarian cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0011] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0012] Figure 1 This is the electrophoresis diagram of the VHH gene fragment of the Anti-MSLN nanobody derived from alpaca;
[0013] Figure 2 This is the SDS-PAGE electrophoresis diagram of Anti-MSLN single domain antibody;
[0014] Figure 3 It is a diagram showing the binding activity of Anti-MSLN single domain antibody to tumor cells. Figure A is for comparison, and Figure B is for MSLN-230 single domain antibody.
[0015] Figure 4 EC50 value of antibody protein binding to MSLN antigen;
[0016] Figure 5 It is the binding affinity between the antibody protein and the MSLN antigen protein. DETAILED DESCRIPTION
[0017] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0018] Example 1 Design and construction of phage display immune alpaca nanoantibody gene library
[0019] (1) Isolation of alpaca peripheral blood lymphocytes and extraction and purification of RNA
[0020] Whole blood was collected from alpacas, peripheral blood lymphocytes were separated, and total RNA was extracted from the separated lymphocytes using an RNA extraction kit (QIAGEN).
[0021] (2) Amplification
[0022] Using the nested PCR amplification method, two rounds of amplification were performed to obtain the alpaca heavy chain VH and light chain VL with high specificity. Then, using the Overlap-PCR method, the heavy chain VH obtained above was connected with the light chain VL by Overlap-PCR to obtain the alpaca nanobody VHH gene fragment. The results are shown in Figure 1 .
[0023] The PCR amplification primer sequences are as follows:
[0024] Light Chain Fd 5'primers:
[0025] YTL-F:GGTGGTCCTGGCTGCNCTN;
[0026] YTL-R:GGGGTACCTGTCATCCACGGACCAGCTGA.
[0027] Heavy Chain Fd 3'primers:
[0028] YTVHH-F:GATCGCCGGCCAGKTGCAGCTCGTGGAGTCNGGNGG;
[0029] YTVHH-R:CATGTGTAGATTCCTGGCCGGCCTGGCCTGAGGAGACGGT GACCTGG.
[0030] (3) The VHH fragment and phage display vector were digested with sfiI (NEB), ligated with T4 ligase (NEB), and then electroporated into TG1 competent cells.
[0031] (4) Identification and preservation of the capacity and diversity of the VHH antibody gene library
[0032] The library capacity was calculated by multiplying the titer measured after transformation by the total amount of transformation: 120 single clones were grown on the plate, 40 single clones were randomly selected, and electroporation titer test was performed, followed by PCR amplification and sequencing identification. 50 colonies were PCR amplified, 49 of which were positive, and the transformation rate reached 98.5%. The library capacity was calculated to be 1.63×10 11 The size of the amplified fragment was the same as the size of the inserted VHH; the sequencing results of 49 clones showed that there were no repeated VHH sequences, and the library capacity and diversity of the antibody gene library met the design requirements.
[0033] Example 2 Preparation of MSLN single domain antibody
[0034] (1) Screening of MSLN single domain antibodies
[0035] Immunotubes were coated with MSLN antigen protein, and 12.5 μg / mL, 25 μg / mL, and 50 μg / mL antigens were used for three rounds of screening, respectively. The tubes were blocked with 4% skim milk PBST, and the above phage library was added for binding for a certain period of time. Non-specific binding phages were removed by washing, and specifically bound phages were eluted with TEA, and then amplified for three rounds of screening.
[0036] Table 1 Affinity screening for enrichment of phage antibodies
[0037] Number of screening rounds Antigen concentration Input phage titer Output phage titer Amplification 1 50 <![CDATA[1×10 12 ]]> <![CDATA[2.76×10 6 ]]> <![CDATA[1.7×10 10 ]]> 2 25 <![CDATA[1×10 12 ]]> <![CDATA[3.1×10 6 ]]> <![CDATA[2.4×10 11 ]]> 3 12.5 <![CDATA[1×10 12 ]]> <![CDATA[1.87×10 5 ]]> -
[0038] (2) ELISA method to measure the culture supernatant of a single clone and screen for positive clones
[0039] A single colony was randomly picked from the agar plate with good growth and separation of single colonies, inoculated into a 96-well culture plate containing 2YT liquid culture medium containing Amp, cultured overnight, centrifuged, and the supernatant was separated. The MSLN antigen protein was used as the antigen to coat a 96-well ELISA plate, and a phage ELISA assay was performed to select the positive well clones of the MSLN antigen protein. DNA sequencing was used to identify the gene sequence of the MSLN antigen protein-specific nanoantibody clone, among which MSLN-230 had the best effect, and its amino acid sequence is shown in SEQ ID No.1.
[0040] SEQ ID No. 1: EVQLQASGGGLVQPGGSLRLSCAASGASYTNSKTAWFR QAPGKGLEFVSAISEHSYPRRYYADSVKGRFTISRDNSKNTLYLQMNSLRAED TAVYYCARFRGSTVTTPSRVPAYWGQGTQVTVSS.
[0041] Table 2 Absorbance of culture plates
[0042] 1 2 3 4 5 6 7 8 9 10 11 12 A 0.3884 0.3044 1.5344 2.6113 0.8078 3.7761 3.3305 0.656 0.334 0.4122 0.3979 0.252 B 1.8102 0.3728 0.8176 0.4274 2.6721 0.4548 1.3424 0.4225 3.5269 0.629 0.8056 0.6388 C 0.3271 1.2843 1.7047 0.7425 0.4751 1.5201 0.8556 0.3156 2.2836 1.2605 0.2974 3.3825 D 1.3607 1.3294 0.1964 0.9677 0.6578 1.8803 2.2366 0.5398 0.8798 0.9813 0.4773 1.2636 E 0.3932 1.2828 0.3595 1.1164 0.2973 1.5616 1.1826 0.8612 0.8781 0.8429 1.8095 0.8739 F 0.6894 1.1427 0.5733 1.6583 0.8391 0.6967 0.6965 0.1454 0.2566 3.4604 1.0648 0.8805 G 0.3408 0.4575 0.3476 0.925 1.0029 1.6153 1.4306 2.2261 0.3625 0.2455 0.846 0.1073 H 0.4005 2.2403 0.7202 0.3608 2.3884 0.1022 0.716 0.879 1.0031 0.5543 0.3749 1.9176
[0043] Example 3 Construction of MSLN single domain antibody expression plasmid
[0044] The specific MSLN-230 gene obtained in Example 2 was amplified by PCR to obtain a PCR product with restriction endonucleases BbsI and BamHI sites. The PCR product and vector (pSJF2 vector) were treated with restriction endonucleases BbsI and BamHI, respectively (Kim Is. Biosic Biochem. 2002, 66 (5): 1148-51). The plasmid VHH-pSJF2 that can be efficiently expressed in Escherichia coli was obtained by ligation and recombination with T4 ligase. The gene sequence was determined to determine the correctness of the sequence.
[0045] Example 4 Expression, purification and identification of specific MSLN single domain antibodies
[0046] (I) Expression and purification of specific MSLN single domain antibodies
[0047] (1) The strain containing the plasmid VHH-pSJF2 described in Example 3 was inoculated on an LB culture plate containing ampicillin at 37°C overnight.
[0048] (2) Select a single colony and inoculate it into 5 ml of LB culture medium containing ampicillin, and culture it at 37°C on a shaking incubator overnight.
[0049] (3) Transfer the culture to 100 ml of 2YT medium containing ampicillin and culture at 37°C in a shaking incubator at 220 rpm. When the OD value reaches 0.6-1.0, add 0.1-0.5 M IPTG and continue culturing overnight.
[0050] (4) Centrifuge at 5000 rpm for 20 min to collect the bacteria.
[0051] (5) The bacteria were washed twice with 0.05 M Tris buffer, and the soluble nanobody expressed in the bacterial periplasm was extracted with hypertonic sucrose. The soluble nanobody protein in the supernatant was collected by centrifugation.
[0052] (6) The nanoantibody protein with a purity of more than 90% was separated by Ni+ ion affinity chromatography magnetic beads (BeaverBeadsTM His-tag Protein Purification, Suzhou Beaver Biomedical Engineering Co., Ltd.).
[0053] Results Figure 2 SDS-PAGE electrophoresis diagram. Figure 2 As shown, MSLN-230-pSJF2 carries c-myc and His6 tags, and the expressed protein molecule is about 25 kd.
[0054] (II) Activity determination of expressed MSLN single domain antibody
[0055] 1. Test materials: ELISA plate (Thermofisher), CD99 antigen protein, Anti-Myc tagantibody-HRP (Beijing Sino Biological), TMB colorimetric solution (Beijing Meikewande, Cat: 1001), coating solution pH 9.6, BSA (Sigma).
[0056] 2. Experimental process:
[0057] 2.1 Coat the cells with MSLN antigen protein at a concentration of 2 μg / ml, 100 μl / well, and incubate at 4°C overnight.
[0058] 2.2 Add 2% skim milk PBS to block, 300 μl / well. Incubate at 37°C for 1.5 h.
[0059] 2.3 Dilute the MSLN antigen protein nanobodies with different numbers to a final concentration of 10.0 μg / mL and 1.0 μg / mL, 100 μL / well.
[0060] 2.4 Dilute Anti-Myc tag antibody (HRP) (1:5000), 100 μl / well, incubate at 37°C for 1 hour.
[0061] 2.5 Add TMB colorimetric solution, 100 μL / well, and react for 10 min in the dark.
[0062] 2.6 Add 50 μl / well 2M HO 2 SO 4 The reaction was terminated and the OD value was measured at a wavelength of 450 nm.
[0063] Figure 3 The results are the experimental results of the activity of the purified MSLN-230 single domain antibody specifically binding to the MSLN antigen protein antigen. According to the test results, it can be seen that the MSLN-230 nano antibody has a high binding activity with the MSLN antigen protein antigen.
[0064] Example 5 Detection of cell binding activity of MSLN single domain antibody
[0065] Test the binding of the screened antibodies to human MSLN protein expressed on CHOK1 cells. Harvest CHO-K1 cells stably expressing human MSLN from flasks. Add 100 μL of 1 × 10 6 Cells at 100 cells / mL were incubated with diluted mouse antibodies on ice for 30 minutes. After washing twice with 200 μL FACS buffer, cells were incubated with secondary antibodies on ice for 30 minutes. Cells were washed twice with 200 μL FACS buffer and transferred to BD Falcon 5mL tubes and analyzed by FACS. The results show that mouse antibodies can bind to human MSLN with high EC50 ( Figure 4 ). EC50 of antibody protein binding to antigen = 2.35.
[0066] Example 6 Affinity determination of MSLN single domain antibody
[0067] First, 1nM biotinylated single domain heavy chain antibody against ovarian cancer specific membrane antigen was incubated with 5 different concentrations (100nM~1500μM) of MSLN antigen in EP tube for 30min; then, 90μL of the mixture was added to the ELISA plate coated with MSLN protein which had been blocked with 3% BSA-PBST, incubated for 10min, the reaction solution was discarded, and washed with PBST; then, 100μL of HRP-labeled streptavidin with a dilution of 1∶2000 was added, incubated for 1h and washed 5 times with PBST; TMB was used for color development and OD450 value was determined. Nonlinear regression analysis was used to obtain the MSLN concentration corresponding to half of the maximum value of OD450. According to the principle of antigen-antibody competitive binding experiment, the affinity constant of the biotinylated nanoantibody against ovarian cancer specific membrane antigen was 2.52×10 -8 M, see the results Figure 5 .
[0068] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A MSLN single domain antibody, characterized in that: The amino acid sequence of the MSLN single domain antibody is shown in SEQ ID No.
1.
2. Use of a MSLN single domain antibody as claimed in claim 1 in the preparation of a drug for treating ovarian cancer.
3. A pharmaceutical composition, characterized in that: Containing the MSLN single domain antibody according to claim 1.
4. A kit, characterized in that: Containing the MSLN single domain antibody according to claim 1.
Citation Information
Patent Citations
Anti-MSLN antibody and pharmaceutical composition for cancer treatment comprising same
CN111247173A
Anti-human MSLN monoclonal antibody and application thereof
CN111349165A
Antibodies against human MSLN and uses thereof
CN116685604A
Anti-Human MSLN Antibody And Application Thereof
US20240124563A1
Anti-human MSLN humanized antibody and use thereof
WO2022262859A1
